Compare · PFE vs THRD
PFE vs THRD
Side-by-side comparison of Pfizer Inc. (PFE) and Third Harmonic Bio Inc. (THRD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PFE and THRD operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- PFE carries a market cap of $153.59B.
- Over the past year, PFE is up 17.1% and THRD is up 4.5% - PFE leads by 12.7 points.
- PFE has hit the wire 10 times in the past 4 weeks while THRD has been quiet.
- PFE has more recent analyst coverage (25 ratings vs 6 for THRD).
- Company
- Pfizer Inc.
- Third Harmonic Bio Inc.
- Price
- $26.98+1.20%
- $5.38-0.09%
- Market cap
- $153.59B
- -
- 1M return
- -1.21%
- -0.92%
- 1Y return
- +17.13%
- +4.47%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2022
- News (4w)
- 10
- 0
- Recent ratings
- 25
- 6
Pfizer Inc.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Prevnar 13/Prevenar 13 (pediatric/adult), Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Pfizer-BioNTech COVID-19 vaccine brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa/Staquis brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Syapse, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Latest PFE
- Bristol Myers Squibb and Pfizer to Make Eliquis® (apixaban) Available via Mark Cuban Cost Plus Drug Company
- Pfizer Declares Second-Quarter 2026 Dividend
- Pfizer Showcases Oncology Innovation and Next-Generation Pipeline at ASCO 2026
- U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
- SEC Form 4 filed by Bourla Albert
- SEC Form 4 filed by Bourla Albert
- SEC Form 3 filed by new insider Hancock Dennis P
- Pfizer Invites Shareholders to View and Listen to Webcast of April 23 Virtual 2026 Annual Meeting of Shareholders
- Telix Strengthens Board with Additional Director Appointments
- AI-Enhanced Robotics in Pharma Manufacturing Signals Major Efficiency, Margin Expansion Opportunities
Latest THRD
- CEO Holles Natalie C. disposed of 1,218,836 shares, closing all direct ownership in the company (SEC Form 4)
- Director Seidel Hans Martin disposed of 85,753 shares, closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Director Soloway Thomas P
- Director Iwicki Mark T disposed of 128,631 shares, closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Chief Financial & Bus. Officer Murphy Christopher M.
- SEC Form 4 filed by Director Gladstone Michael
- Director Bonita David P disposed of 5,779,071 shares, closing all direct ownership in the company (SEC Form 4)
- SEC Form 15-12G filed by Third Harmonic Bio Inc.
- SEC Form EFFECT filed by Third Harmonic Bio Inc.
- SEC Form 8-K filed by Third Harmonic Bio Inc.